Foresite Capital
SEC-registered investment adviser.
- HQ
- CA
Foresite Capital is a multi-stage healthcare and life sciences investment firm that funds promising businesses at all stages of their life cycles. It announced a new fundraise described as making big bets in one of the best biotech investment environments. The firm has added Jorge Reis-Filho as a Venture Partner. Its portfolio names include Kriya Therapeutics, Eikon Therapeutics, Xaira Therapeutics, and Denali Therapeutics.
New fund likely raising soon
The firm's newest fund is 4 to 7 years past its first sale and no newer Form D has been filed.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Pre-seed, Seed, Series A, Series B, Growth | Not enough dated deals | Growth, Series B, Series A |
| Sectors | Healthtech, Biotech | Not enough dated deals | Biotech, Healthtech, Medical devices, Life sciences and research tools |
| Regions | Not stated | Not enough dated deals | CA, MA |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2012 | 1 | Biotech, Healthtech, Medical devices |
| 2013 | 3 | Biotech, Healthtech, Medical devices |
| 2014 | 8 | Healthtech, Biotech, Medical devices |
| 2015 | 13 | Biotech, Healthtech, Medical devices |
| 2016 | 5 | Biotech, Healthtech, Medical devices |
| 2017 | 7 | Healthtech, Biotech, Medical devices |
| 2018 | 17 | Biotech, Healthtech, Life sciences and research tools |
| 2019 | 10 | Biotech, Healthtech, Life sciences and research tools |
| 2020 | 14 | Biotech, Healthtech, Life sciences and research tools |
Stage mix over time
- Pre-seed
- Seed
- Series A
- Series B
- Growth
| Year | Pre-seed | Seed | Series A | Series B | Growth |
|---|---|---|---|---|---|
| 2012 | 0 | 0 | 0 | 1 | 0 |
| 2013 | 0 | 0 | 0 | 1 | 2 |
| 2014 | 0 | 0 | 1 | 5 | 2 |
| 2015 | 0 | 0 | 0 | 5 | 7 |
| 2016 | 0 | 0 | 0 | 1 | 4 |
| 2017 | 0 | 0 | 2 | 3 | 2 |
| 2018 | 0 | 1 | 1 | 5 | 9 |
| 2019 | 0 | 0 | 3 | 2 | 5 |
| 2020 | 0 | 0 | 2 | 4 | 7 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Foresite Capital Fund VI LP Foresite Capital is a multi-stage healthcare and life sciences investor. It backs companies that leverage biology and big data, focusing on the intersection of tech and biotech, from incubation through IPO. Inferred from the firm's website | 2022 | $551.1M to $722.85M (Form D and SEC adviser filing) | Late investment period |
| Foresite Capital VI-A, LLC Foresite Capital is a multi-stage healthcare and life sciences investor. It backs companies that leverage biology and big data, focusing on the intersection of tech and biotech, from incubation through IPO. Inferred from the firm's website | approx. 2021 | $17.21M to $20.12M (Form D and SEC adviser filing) | Late investment period |
| Foresite Labs Fund I, L.P. | approx. 2021 | $150M to $153.51M (Form D and SEC adviser filing) | Follow-ons only |
| Foresite Capital Fund V, L.P. | 2019 | $743M to $909.02M (Form D and SEC adviser filing) | Follow-ons only |
03 · People across funds
- James Tananbaum, Managing Member of the General Partner of Issuer
Foresite Capital Fund VI LP (Named on Form D); Foresite Capital VI-A, LLC (Named on Form D); Foresite Labs Fund I, L.P. (Named on Form D); Foresite Capital Fund V, L.P. (Named on Form D)
- Collin Yang-Wong, Principal
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Deepak Atri, Principal
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Dorothy Margolskee, Managing Director
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Hadi Tabbaa, Managing Director
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Hyung Chun, Partner
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Jim Tananbaum, Founder & CEO
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Jorge Reis-Filho, Venture Partner
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Liang Chang, Venture Partner
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Michael Rome, Managing Director
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Mike Lai, Venture Partner
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Peter Wung, Venture Partner
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Richard Lau, Managing Director
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Shannon Bergstedt, Partner
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Stephen C. Peterson, Managing Director
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Travis Young, Venture Partner
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Uplaksh Kumar, Venture Partner
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Vishal Deshmukh, Principal
Foresite Capital Fund VI LP (Team); Foresite Capital VI-A, LLC (Team); Foresite Labs Fund I, L.P. (Team); Foresite Capital Fund V, L.P. (Team)
- Deepak Atri, MD, Principal
On the team page, not linked to a fund
- Dorothy Margolskee, MD, Managing Director
On the team page, not linked to a fund
- Hyung Chun, MD, Partner
On the team page, not linked to a fund
- Jim Tananbaum, MD, Founder & CEO
On the team page, not linked to a fund
- Michael Rome, PhD, Managing Director
On the team page, not linked to a fund
- Richard Lau, CFA, Managing Director
On the team page, not linked to a fund
- Stephen C. Peterson, CFA, Managing Director
On the team page, not linked to a fund
- Vishal Deshmukh, PhD, Principal
On the team page, not linked to a fund
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
- New fundForesite News Archives – Foresite CapitalUndated
- Team changePress Releases Archives – Foresite CapitalUndated
06 · Sources
- https://www.foresitecapital.com/contact/
- https://www.foresitecapital.com/
- https://www.foresitecapital.com/people
- https://www.foresitecapital.com/portfolio
- https://www.foresitecapital.com/news/news-type/press-releases/
- https://www.foresitecapital.com/strategy
- https://www.foresitecapital.com/news/news-type/foresite-news/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026